Phase 4 N=189 Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
Ocular Hypertension · Open Angle Glaucoma
Primary: Mean Diurnal Intraocular Pressure (IOP) at Week 6 — 17.01; 20.37 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=258 Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
Back Pain · Low Back Pain · Neuropathic Pain
Primary: Change in the Average Pain Intensity Score on an 11-point Numeric Rating Scale (NRS-3) — -3.7; -2.7 units on a scale
Phase 4 N=545 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With an Adverse Event (AE) - Overall Summary — 67.4; 5.8; 20.2; 0.2 percentage of participants
Phase 4 N=4,766 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive…
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
Phase 4 N=229 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 14; 7; 1; 171 participant exams — p=0.8516
Phase 4 N=20 Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week — 0.069; 0.010; 0.121; 0.023 Liters
Phase 4 N=89 Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery
Pain, Postoperative
Primary: Postoperative Opioid Use During the Postanesthesia Care Unit (PACU) Stay, and the First 24 Hours Postoperatively — 5.3; 5.2; 39.6; 32.7 mg — p=0.828
Phase 4 N=24 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months
Phase 4 N=25 A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
Influenza · Common Cold
Primary: Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter) — 4.59; 23.14 minutes — p=0.0004
Phase 4 N=456 Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana
Rotavirus Gastroenteritis
Primary: Immunoglobulin A (IgA) Seroconversion: 6 & 10 Week vs. 6, 10, & 14 Week Vaccination Schedules — 28.9; 43.4 percentage of participants — p=0.014
Phase 4 N=96 The Feasibility of Florbetapir Quantitation
Alzheimers Disease
Primary: Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers) — 81.7; 88.8; 7.1 Percent Accuracy — p=0.0029
Phase 4 N=207 The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
Epilepsy
Primary: Retention Rate After 52 Weeks Maintenance Period — 104; 98 participants
Phase 4 N=107 Early Whole Blood in Patients Requiring Transfusion After Major Trauma
Trauma/Injury Problem
Primary: Units of Blood Products Required During the First 24 Hours After Emergency Department Admission — 12; 13 units of blood
Phase 4 N=150 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale